metformin glp-1 combination weight loss Does work for loss? National Institute for Health and

Trends Endocrinol Metab 2020;31:410-21.ArticlePubMed 136

Today, two GLP-1RAs, liraglutide and semaglutide, are approved for the purpose of weight loss as an adjunct to lifestyle therapy

More importantly, the hazard ratio for major adverse cardiovascular events (including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) for the pooled tirzepatide groups versus glargine was 0.74 (95% CI 0.511.08), suggesting no increased cardiovascular risk with tirzepatide compared to insulin glargine

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

Sitagliptin reduces albuminuria in patients with type 2 diabetes

Concomitantly, the increased levels of insulin reduce the binding of liver sex hormone binding globulin SHBG to testosterone, leading to hyperandrogenism (153)